@article{JiménezAñón:111981,
author = "Jiménez Añón, Marta and Lanuza Giménez, Fco. Javier
and Jiménez Caudevilla, Carlos",
title = "{Metformina y Acidosis láctica}",
year = "2018",
note = "Metformin (Biguanide) is the most commonly used oral
antidibbetic agent in Type 2 Diabetes Mellitus. It has an
advantage over Sulfonylureas due to its lower degree of
hypoglycaemia and its beneficial effects in hyperlipemia.
It has also been observed that weight decreases slightly,
making it the first choice in obese patients. Regarding
their adverse reactions, the most frequent are
gastrointestinal, however, the most serious and infrequent
is lactic acidosis (the reason for our study) that occurs
when toxic doses of metformin are given or normal doses in
patients with factors of risk for lactic acidosis (Heart
failure, renal or hepatic, COPD ... etc). In this work, in
addition to a brief review of the treatment of type 2 DM,
we will analyze the current evidence in relation to
Metformin and lactic acidosis, as well as what the risk
groups are and what measures should be taken. Finally, we
will address the problem that arises in the emergency
services at the time of differentiation, in patients who
take metformin and have a fever, if the increase in lactic
acid is due to taking metformin or to have a severe sepsis",
}